Shilpa Medicare (SHILPAMED) — Announcement

📢 Key Event
Shilpa Biologicals upgraded to IND A+ rating with Stable outlook

🔄 What Changed
Upgraded from previous rating (not specified in filing)

💡 Investor Takeaway
The upgrade indicates improved creditworthiness for the subsidiary, potentially lowering borrowing costs and boosting investor confidence in the group's financial stability.

Shilpa Medicare announced that its material subsidiary Shilpa Biologicals received an upgraded credit rating of IND A+ from India Ratings and Research, with a Stable outlook, reflecting improved financial health and lower default risk for its bank facilities. This rating action signals stronger creditworthiness for the subsidiary, which may enhance investor confidence in the group's overall financial stability and borrowing capacity.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SHILPAMED ✨ Ask AI About This

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,391.14 Cr P/E: 48.2 ROE: 12.5% ROCE: 13.4% Div Yield: 0.07%

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

💡 Ask AI about this filing

"How does this rating compare to peers in the pharma subsidiary space?" "What impact will this have on SHILPAMED's consolidated borrowing costs?" "When will the upgraded rating be reflected in the group's financial statements?"

Ask AI Free →

📊 More SHILPAMED filings

See all SHILPAMED filings →

🔥 Also filed on 16 July 2026

VALUEIND Value Industries Limited Announcement ARFIN Arfin India Limited Insider Trading KTKBANK The Karnataka Bank Limited Corporate Action GREENPLY Greenply Industries Limited Corporate Action LTM LTM Limited Financial Results SIGIND Signet Industries Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd